Jenessa Smith
Jenessa Smith
ArsenalBio
Dirección de correo verificada de arsenalbio.com
Título
Citado por
Citado por
Año
Lessons learned from the clinical development and market authorization of Glybera
LM Bryant, DM Christopher, AR Giles, C Hinderer, JL Rodriguez, JB Smith, ...
Human gene therapy Clinical development 24 (2), 55-64, 2013
1982013
B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look
JB Smith, C Stashwick, DJ Powell Jr
Gynecologic oncology 134 (1), 181-189, 2014
732014
Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma
MK Panjwani, JB Smith, K Schutsky, J Gnanandarajah, CM O'connor, ...
Molecular Therapy 24 (9), 1602-1614, 2016
662016
Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor
K Schutsky, DG Song, R Lynn, JB Smith, M Poussin, M Figini, Y Zhao, ...
Oncotarget 6 (30), 28911, 2015
322015
Tumor regression and delayed onset toxicity following B7-H4 CAR T cell therapy
JB Smith, E Lanitis, D Dangaj, E Buza, M Poussin, C Stashwick, ...
Molecular Therapy 24 (11), 1987-1999, 2016
262016
A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma
DL Hermanson, BE Barnett, S Rengarajan, R Codde, X Wang, Y Tan, ...
Blood 128 (22), 2127-2127, 2016
232016
CD4+ T-helper type 1 cytokines and trastuzumab facilitate CD8+ T-cell targeting of HER2/neu–expressing cancers
J Datta, S Xu, C Rosemblit, JB Smith, JA Cintolo, DJ Powell, ...
Cancer immunology research 3 (5), 455-463, 2015
212015
A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes
E Lanitis, JB Smith, D Dangaj, S Flingai, M Poussin, S Xu, BJ Czerniecki, ...
Human gene therapy 25 (8), 730-739, 2014
152014
PiggyBac™-Produced CAR-T Cells Exhibit Stem-Cell Memory Phenotype
BE Barnett, DL Hermanson, JB Smith, X Wang, Y Tan, CE Martin, ...
Target 929, K562, 2016
132016
B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/-and Patient-Derived Multiple Myeloma Tumors
R Mathur, BE Barnett, D Hermanson, J He, Z Zhang, S Rengarajan, ...
Blood 130 (Suppl 1), 3068-3068, 2017
72017
Production of Universal Anti-Bcma CAR-T Cells with Reduced Alloreactivity, but Potent Effector Function for the Treatment of Multiple Myeloma
X Wang, BE Barnett, C Martin, D Hermanson, X Li, J Smith, J Wu, ...
Blood 130 (Suppl 1), 503-503, 2017
42017
Feasibility and safety of cCD20 RNA CAR-bearing T cell therapy for the treatment of canine B cell malignancies
JB Smith, MK Panjwani, K Schutsky, J Gnanandarajah, S Calhoun, ...
Journal for immunotherapy of cancer 3 (S2), P123, 2015
32015
Abstract A071: PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model
JB Smith, R Codde, Y Tan, BE Barnett, D Hermanson, S Rengarajan, ...
Cancer Research 78 (16 Supplement), A071-A071, 2018
22018
PiggyBac-manufactured anti-BCMA Centyrin-based CAR-T therapeutic exhibits improved potency and durability
D Hermanson, BE Barnett, S Rengarajan, R Codde, X Wang, Y Tan, ...
Cancer Research 77, 2017
22017
High Fidelity Genome Editing Using NextGEN™ CRISPR (Clo51-dCas9) System for the Production of Allogeneic CAR-T Cells
X Wang, X Li, B Barnett, C Martin, D Hermanson, J Smith, S Rengarajan, ...
Journal of Clinical Oncology 35, 2017
22017
P-BCMA-ALLO1—a non-viral allogeneic anti-BCMA CAR T therapy with potent anti-tumor function for the treatment of multiple myeloma
M Richter, S Cranert, Y Tan, M Tong, C Domingo, E Argus, S Ibitokou, ...
JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019
12019
PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model
JB Smith, R Codde, Y Tan, BE Barnett, D Hermanson, S Rengarajan, ...
JOURNAL FOR IMMUNOTHERAPY OF CANCER 5, 2017
12017
Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor
N Mason, DJ Powell, MK Panjwani, J Smith
US Patent App. 15/743,033, 2019
2019
A Novel MUC1-Specific CAR-T Therapy (P-MUC1C-101) for Treatment of Multiple Solid Tumors
JB Smith, X Wang, Y Tan, R Codde, J Fritz, P Ghoroghchian, EM Ostertag, ...
MOLECULAR THERAPY 27 (4), 268-269, 2019
2019
Gene Modification of Human T Cells via Piggyback Yields an Anti-BCMA CARTyrin Cellular Product with Durable Efficacy
D Hermanson, B Barnett, X Wang, R Mathur, J He, S Rengarajan, X Li, ...
MOLECULAR THERAPY 25 (5), 53-53, 2017
2017
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20